The application of prostate-specific antigen (PSA) in prostate cancer (PC) screening,
diagnosis, and prognosis has improved the clinical management of PC patients. However …

INTRODUCTION: Due to its universal applicability for early detection and prediction of
cancer stage and disease recurrence, widespread implementation of serum-based prostate …

Since the introduction of serum prostate-specific antigen (PSA) screening 25 years ago,
prostate cancer diagnosis and management have been guided by this biomarker. Yet, PSA …

Although prostate-specific antigen (PSA) remains the most used test to detect prostate
cancer (PCa), the limited specificity and an elevated rate of overdiagnosis are the main …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

Although prostate cancer (PCa) is the most commonly diagnosed cancer in men, most
patients do not die from the disease. Prostate specific antigen (PSA), the most widely used …

Prostate-specific antigen (PSA) is a protein produced by the prostate, and this protein may
be elevated for several reasons, including prostatitis, benign prostatic hypertrophy and/or …

Prostate-specific antigen (PSA) is widely used as a biomarker in the detection of prostate
cancer and for decision making regarding treatment options, response to therapy, and …

Background The use of biomarkers for prostate cancer screening, diagnosis and prognosis
has the potential to improve the clinical management of the patients. Owing to inherent …

The use of biomarkers for prostate cancer (PCa) screening, detection, and prognostication
have revolutionized the diagnosis and management of the disease. Current clinical practice …